I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Machiels, J-P
38
results:
Search for persons
X
Format
Online (38)
Mediatypes
Articles (Online) (13)
OpenAccess-fulltext (25)
Languages
english (35)
french (1)
Sorted by: Relevance
Sorted by: Year
?
1
43O A dose-escalation study of TNO155 (TN) in combination w..:
Santa Gadea, O. Saavedra
;
Machiels, J-P.
;
Soo, R.A.
...
ESMO Open. 9 (2024) - p. 102272 , 2024
Link:
https://doi.org/10.1016/..
?
2
186P Post-anti-PD1 tumor characterization of HPV-negative R..:
Van Der Elst, A.
;
Saboya, D. Herrero
;
Michon, L.
...
Immuno-Oncology and Technology. 20 (2023) - p. 100645 , 2023
Link:
https://doi.org/10.1016/..
?
3
155P A phase I study exploring the safety and tolerability ..:
Prenen, H.
;
Lesimple, T.
;
Robert, M.
...
Immuno-Oncology and Technology. 20 (2023) - p. 100666 , 2023
Link:
https://doi.org/10.1016/..
?
4
195P IMMUcan: Toward a better understanding of the tumor mi..:
Morfouace, M.
;
Buisseret, L.
;
Besse, B.
...
Immuno-Oncology and Technology. 20 (2023) - p. 100654 , 2023
Link:
https://doi.org/10.1016/..
?
5
32P Tumor-agnostic plasma assay for circulating tumor DNA p..:
Honoré, N.
;
Van Der Elst, A.
;
Dietz, A.
...
Immuno-Oncology and Technology. 20 (2023) - p. 100501 , 2023
Link:
https://doi.org/10.1016/..
?
6
206P Characterization of the immune microenvironment of rec..:
van der Elst, A.
;
Herrero, D.
;
Morfouace, M.
...
Immuno-Oncology and Technology. 16 (2022) - p. 100317 , 2022
Link:
https://doi.org/10.1016/..
?
7
Patient (pt) reported pain and health-related quality of li..:
Saad, F.
;
Stenzl, A.
;
Mehra, N.
...
European Urology Open Science. 45 (2022) - p. S172-S174 , 2022
Link:
https://doi.org/10.1016/..
?
8
Health-Related Quality of Life (HRQoL) in men with metastat..:
Stenzl, A.
;
Saad, F.
;
De Bono, J.S.
...
European Urology Open Science. 33 (2021) - p. S198-S199 , 2021
Link:
https://doi.org/10.1016/..
?
9
Patient-reported pain by baseline pain status in men with m..:
Stenzl, A.
;
Saad, F.
;
De Bono, J.S.
...
European Urology Open Science. 33 (2021) - p. S308-S309 , 2021
Link:
https://doi.org/10.1016/..
?
10
P-24 Circulating tumor DNA as a marker of Minimal Residual ..:
Honoré, N.
;
Galot, R.
;
van Marcke, C.
...
Oral Oncology. 118 (2021) - p. 11 , 2021
Link:
https://doi.org/10.1016/..
?
11
772 Which factors predict overall survival in metastatic ca..:
Van Praet, C.
;
Rottey, S.
;
Van Hende, F.
...
European Urology Supplements. 15 (2016) 3 - p. e772-e772a , 2016
Link:
https://doi.org/10.1016/..
?
12
PP 72 Angiogenesis-related cytokines as potential predictiv..:
Seront, E.
;
Rottey, S.
;
Sautois, B.
...
European Journal of Cancer. 47 (2011) - p. S30 , 2011
Link:
https://doi.org/10.1016/..
?
13
Détection par RT-PCR de métastases circulantes dans les gre..:
Salmon, MA
;
Jurdan, MJ
;
Feyens, AM
...
Immuno-analyse & Biologie Spécialisée. 12 (1997) 5 - p. 247-251 , 1997
Link:
https://doi.org/10.1016/..
?
14
Pembrolizumab versus methotrexate, docetaxel, or cetuximab ..:
Harrington, KJ
;
Cohen, EEW
;
Soulières, D
...
ARTN 106587. , 2024
Link:
https://repository.icr.a..
?
15
Durvalumab with or without tremelimumab versus the EXTREME ..:
Psyrri, A
;
Fayette, J
;
Harrington, K
...
S0923-7534(22)04778-0. , 2023
Link:
https://repository.icr.a..
1-15